What’s new

• FY27 international revenue growth guided at 18-20% with stable EBITDA margin.
• EU-GMP inspection at two sites in March 2026 led to procedural non-compliance observations.
• Commercialisation of EU-CDMO pipeline delayed; minimal impact on existing business.

Why it matters

Eris is now providing explicit international growth targets for the first time, adding modelling clarity for a segment that was previously opaque. However, the EU regulatory hit introduces a near-term overhang, suggesting the pipeline ramp-up will take longer than hoped. The domestic branded biz guidance remains unchanged at 1.3x therapy growth and 37% EBITDA margin.

What we’re watching

• Timeline for closure of EU-GMP observations and re-inspection.
• FY27 execution on the international revenue target, especially EU-CDMO contribution.
• Whether domestic branded growth sustains at 1.3x therapy market growth.

The full read

Eris Lifesciences has given the street its first explicit FY27 target for the international business: 18-20% revenue growth with EBITDA margins held at FY26 levels. That is a fresh data point for a segment that investors have been trying to size up. But the same presentation also reveals that an EU-GMP inspection in March 2026 turned up procedural non-compliance observations at two manufacturing sites, delaying the EU-CDMO pipeline commercialisation. Existing operations took minimal hit. The domestic branded formulations guidance (a rehash from the Q4 concall) targets 1.3x therapy market growth and 37% EBITDA margin. The net read: international visibility improves, but a regulatory overhang tempers the excitement. The open question is how fast Eris clears those observations and gets the pipeline back on track.

Primary source: BSE · NSE